LLY ELI LILLY & Co
Pharmaceutical Preparations · NYSE · SEC CIK 59478 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY45.5%
TTM net income YoY49.8%
TTM EPS YoY50.7%
Revenue 3-yr CAGR39.2%
Net income 3-yr CAGR76.8%
Margins
Gross margin83.6%
Operating margin—
Net margin31.9%
FCF margin—
EBITDA margin—
Returns
ROE86.1%
ROA21.0%
ROIC (approx.)—
Asset turnover0.66x
Leverage & solvency
Liabilities / assets72.8%
Debt / equity1.23x
Current ratio1.39x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.11x
Accruals ratio-2.3%
Payout ratio21.7%
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $65.18B | $45.04B | $34.12B | $28.54B | $28.32B |
| Cost of revenue | $11.05B | $8.42B | $7.08B | $6.63B | $7.31B |
| Gross profit | $54.13B | $36.62B | $27.04B | $21.91B | $21.01B |
| R&D expense | $13.34B | $10.99B | $9.31B | $7.19B | $6.93B |
| SG&A expense | $11.09B | $8.59B | $7.40B | $6.44B | $6.43B |
| Interest expense | $895.00M | $781.00M | $486.00M | $331.60M | $339.80M |
| Pretax income | $25.73B | $12.68B | $6.55B | $6.81B | $6.16B |
| Income tax | $5.09B | $2.09B | $1.31B | $561.60M | $573.80M |
| Net income | $20.64B | $10.59B | $5.24B | $6.24B | $5.58B |
| EPS (basic) | 23.00 | 11.76 | 5.82 | 6.93 | 6.15 |
| EPS (diluted) | 22.95 | 11.71 | 5.80 | 6.90 | 6.12 |
| Dividends declared per share | 6.23 | 5.40 | 4.69 | 4.07 | 3.53 |
| Weighted avg. shares (diluted) | 899.30M | 904.10M | 903.30M | 904.62M | 911.68M |
| Balance sheet | |||||
| Cash & equivalents | $7.27B | $3.27B | $2.82B | $2.07B | $3.82B |
| Short-term investments | — | $154.80M | $109.10M | $144.80M | $90.10M |
| Receivables | $17.76B | $11.01B | $9.09B | $6.90B | $6.67B |
| Inventory | $13.74B | $7.59B | $5.77B | $4.31B | $3.89B |
| Current assets | $55.63B | $32.74B | $25.73B | $18.03B | $18.45B |
| PP&E, net | $24.68B | $17.10B | $12.91B | $10.14B | $8.99B |
| Goodwill | $5.90B | $5.77B | $4.94B | $4.07B | $3.89B |
| Intangibles | $6.52B | $6.17B | $6.91B | $7.21B | $7.69B |
| Total assets | $112.48B | $78.72B | $64.01B | $49.49B | $48.81B |
| Current liabilities | $35.23B | $28.38B | $27.29B | $17.14B | $15.05B |
| Short-term debt | $1.64B | $5.12B | $6.90B | $1.50B | $1.54B |
| Long-term debt | $40.87B | $28.53B | $18.32B | $14.74B | $15.35B |
| Total debt | $42.50B | $33.64B | $25.23B | $16.24B | $16.88B |
| Total liabilities | $85.94B | $64.44B | $53.14B | $38.71B | $39.65B |
| Shareholders' equity | $26.54B | $14.27B | $10.77B | $10.65B | $8.98B |
| Net debt | $35.23B | $30.38B | $22.41B | $14.17B | $13.07B |
| Cash flow statement | |||||
| Operating cash flow | $16.81B | $8.82B | $4.24B | $7.59B | $7.37B |
| Investing cash flow | -$10.97B | -$9.30B | -$7.15B | -$3.76B | -$2.87B |
| Financing cash flow | -$2.21B | $1.23B | $3.50B | -$5.41B | -$4.13B |
| Depreciation & amortization | $2.00B | $1.77B | $1.53B | $1.52B | $1.55B |
| Stock-based compensation | $626.00M | $646.00M | $629.00M | $371.10M | $342.80M |
| Dividends paid | $5.38B | $4.68B | $4.07B | $3.54B | $3.09B |
| Share buybacks | $4.11B | $2.50B | $750.00M | $1.50B | $1.25B |
Free plan shows the latest 5 periods; Pro shows all 19 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.